(RTTNews) – The actions of drug manufacturer Kamada Ltd. (KMDA) rose more than 7% on Tuesday morning after announcing the first positive intermediate effects of the ongoing Phase 1/2 test on its drug candidate for Covid-19 remedy.
He demonstrated that symptoms progressed in 11 out of 12 patients treated with the company’s hyperimmune immunoglobulin (IgG) plasma-derived product anti-SRAS-CoV-2. All 11 patients were discharged from the hospital within four to five days of treatment. .
The most productive effects will occur until January 2021.
KMDA shares are lately at $9. 40. Se traded between $4. 40 and $13. 33 over the following year.